Retinal blood flow velocities in infants with retinopathy of prematurity after intravitreal administration of bevacizumab.

Eur J Ophthalmol · 2024 · PMC10757389 · PMID 37218176

Europe PMC DOI

hedged sentence

0.0510

closest p · 1.0× alpha

0.0510

boldest claim

The sentences

borderline significancep = .051so close (0.05 < p ≤ 0.1)

However, significant differences remained also in the third exam between bevacizumab-treated and control eyes for CRA peak systolic velocity (p = .002), end-diastolic velocity (p = .018) and velocity time integral (p = .002) but not resistance index (p = .412), while the difference for CRV maximum velocity attained borderline significance (p = .051).

also in 4,327 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.